Marie-Céline Deau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marie-Céline Deau has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Sven Kracker
Université Paris Cité, Paris, France
7 shared publications Alain Fischer
Université Paris Descartes-Sorbonne Paris Cité, Imagine Institute, Paris, France
6 shared publications- Marina Cavazzana
Imagine Institute, Paris, France
6 shared publications - Anne Durandy
INSERM, Unité U768, Hôpital Necker Enfants-Malades, Paris, France
5 shared publications - Lucie Heurtier
Laboratory of Human Lymphohematopoiesis, INSERM UMR 1163, Imagine Institute, Paris, France
4 shared publications Capucine Picard
Université Paris Descartes, Sorbonne Paris Cité, Imagine Institute, Paris, France
3 shared publications
Latest Publications
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Dissection des spécificités fonctionnelles des facteurs de transcription de la famille d’Ikaros au cours du développement précoce des lymphocytes B
Bien que beaucoup de facteurs de transcription puissent former des homo- et hétérodimères, les fonctions de ces derniers ne sont pas clairement identifiées. Nous avons adressé cette question pour les facteurs de transcription de la famille d’Ikaros exprimés au cours de la différenciation des lymphocytes B : Ikaros et Aiolos. Ces facteurs possèdent un domaine de dimérisation permettant la formation d’homo-et d’hétérodimères. Pour définir le rôle des différents dimères dans la différenciation des lymphocytes pré-B, nous avons utilisé une lignée de lymphocytes pré-B murins déficients pour Ikaros. Nous avons analysé les profils de liaison à l’ADN des différents dimères et nous avons montré que l’homodimère d’Ikaros se lie à peu de régions sur le génome et que ces régions sont également liées par l’homodimère d’Aiolos et l’hétérodimère Ikaros/Aiolos. Il est possible qu’Ikaros se dimérise préférentiellement avec Aiolos dès que celui-ci est exprimé. Cette étude montre pour la première fois des différences fonctionnelles majeures entre les membres de la famille d’Ikaros et suggère que les hétérodimères puissent être les médiateurs clés de leurs fonctions.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Dissection des spécificités fonctionnelles des facteurs de transcription de la famille d’Ikaros au cours du développement précoce des lymphocytes B
Bien que beaucoup de facteurs de transcription puissent former des homo- et hétérodimères, les fonctions de ces derniers ne sont pas clairement identifiées. Nous avons adressé cette question pour les facteurs de transcription de la famille d’Ikaros exprimés au cours de la différenciation des lymphocytes B : Ikaros et Aiolos. Ces facteurs possèdent un domaine de dimérisation permettant la formation d’homo-et d’hétérodimères. Pour définir le rôle des différents dimères dans la différenciation des lymphocytes pré-B, nous avons utilisé une lignée de lymphocytes pré-B murins déficients pour Ikaros. Nous avons analysé les profils de liaison à l’ADN des différents dimères et nous avons montré que l’homodimère d’Ikaros se lie à peu de régions sur le génome et que ces régions sont également liées par l’homodimère d’Aiolos et l’hétérodimère Ikaros/Aiolos. Il est possible qu’Ikaros se dimérise préférentiellement avec Aiolos dès que celui-ci est exprimé. Cette étude montre pour la première fois des différences fonctionnelles majeures entre les membres de la famille d’Ikaros et suggère que les hétérodimères puissent être les médiateurs clés de leurs fonctions.
- Open Access
- 23 June 2025
- Published by Springer Nature in EMBO Reports
- Vol. 26 (16) , 4040-4071
LRBA deficiency impairs autophagy and contributes to enhanced antigen presentation and T-cell dysregulation
Reduced autophagy is associated with the aberrant humoral response observed in lipopolysaccharide-responsive beige-like anchor protein (LRBA) deficiency; however, the molecular mechanisms and their impact on T-cell responses remain poorly understood. We identify two novel LRBA interactors, phosphoinositide 3-kinase regulatory subunit 4 (PIK3R4) and FYVE And Coiled-Coil Domain Autophagy Adaptor 1 (FYCO1), which each play key roles in autophagy. PIK3R4 facilitates the production of phosphatidylinositol-3 phosphate (PI(3)P) that promotes autophagosome formation and autophagosome-lysosome fusion, whereas FYCO1 supports autophagosome movement. LRBA-knockout (KO) cells show impaired PI(3)P production, reduced autophagosome-lysosome fusion, accumulation of enlarged autophagosomes, and decreased cargo degradation. In line with the role of autophagy as a major degradation system for MHC-II loading and antigen presentation, we observe increased numbers of MHC class II and LC3 vesicles, along with enhanced antigen presentation in absence of LRBA, resulting in a higher production of proinflammatory cytokines from T cells in vitro. Our work suggests a novel biological role of LRBA controlling antigen presentation and T-cell responses by positively regulating autophagy, which may contribute to T-cell immune dysregulation observed in LRBA-deficient patients.
- 23 June 2025
- Published by Springer Nature in EMBO Reports
- Vol. 26 (16) , 4040-4071
Open AccessLRBA deficiency impairs autophagy and contributes to enhanced antigen presentation and T-cell dysregulation
Reduced autophagy is associated with the aberrant humoral response observed in lipopolysaccharide-responsive beige-like anchor protein (LRBA) deficiency; however, the molecular mechanisms and their impact on T-cell responses remain poorly understood. We identify two novel LRBA interactors, phosphoinositide 3-kinase regulatory subunit 4 (PIK3R4) and FYVE And Coiled-Coil Domain Autophagy Adaptor 1 (FYCO1), which each play key roles in autophagy. PIK3R4 facilitates the production of phosphatidylinositol-3 phosphate (PI(3)P) that promotes autophagosome formation and autophagosome-lysosome fusion, whereas FYCO1 supports autophagosome movement. LRBA-knockout (KO) cells show impaired PI(3)P production, reduced autophagosome-lysosome fusion, accumulation of enlarged autophagosomes, and decreased cargo degradation. In line with the role of autophagy as a major degradation system for MHC-II loading and antigen presentation, we observe increased numbers of MHC class II and LC3 vesicles, along with enhanced antigen presentation in absence of LRBA, resulting in a higher production of proinflammatory cytokines from T cells in vitro. Our work suggests a novel biological role of LRBA controlling antigen presentation and T-cell responses by positively regulating autophagy, which may contribute to T-cell immune dysregulation observed in LRBA-deficient patients.
- Open Access
- 30 August 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (10)
Helios represses megakaryocyte priming in hematopoietic stem and progenitor cells
Our understanding of cell fate decisions in hematopoietic stem cells is incomplete. Here, we show that the transcription factor Helios is highly expressed in murine hematopoietic stem and progenitor cells (HSPCs), where it is required to suppress the separation of the platelet/megakaryocyte lineage from the HSPC pool. Helios acts mainly in quiescent cells, where it directly represses the megakaryocyte gene expression program in cells as early as the stem cell stage. Helios binding promotes chromatin compaction, notably at the regulatory regions of platelet-specific genes recognized by the Gata2 and Runx1 transcriptional activators, implicated in megakaryocyte priming. Helios null HSPCs are biased toward the megakaryocyte lineage at the expense of the lymphoid and partially resemble cells of aging animals. We propose that Helios acts as a guardian of HSPC pluripotency by continuously repressing the megakaryocyte fate, which in turn allows downstream lymphoid priming to take place. These results highlight the importance of negative and positive priming events in lineage commitment.
- 30 August 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (10)
Open AccessHelios represses megakaryocyte priming in hematopoietic stem and progenitor cells
Our understanding of cell fate decisions in hematopoietic stem cells is incomplete. Here, we show that the transcription factor Helios is highly expressed in murine hematopoietic stem and progenitor cells (HSPCs), where it is required to suppress the separation of the platelet/megakaryocyte lineage from the HSPC pool. Helios acts mainly in quiescent cells, where it directly represses the megakaryocyte gene expression program in cells as early as the stem cell stage. Helios binding promotes chromatin compaction, notably at the regulatory regions of platelet-specific genes recognized by the Gata2 and Runx1 transcriptional activators, implicated in megakaryocyte priming. Helios null HSPCs are biased toward the megakaryocyte lineage at the expense of the lymphoid and partially resemble cells of aging animals. We propose that Helios acts as a guardian of HSPC pluripotency by continuously repressing the megakaryocyte fate, which in turn allows downstream lymphoid priming to take place. These results highlight the importance of negative and positive priming events in lineage commitment.
- Open Access
- 30 May 2019
- Published by Wiley in British Journal of Haematology
- Vol. 186 (5) , E155-E159
Large deletions of the 5′ region of IKZF1 lead to haploinsufficiency in B‐cell precursor acute lymphoblastic leukaemia
- 30 May 2019
- Published by Wiley in British Journal of Haematology
- Vol. 186 (5) , E155-E159
Open AccessLarge deletions of the 5′ region of IKZF1 lead to haploinsufficiency in B‐cell precursor acute lymphoblastic leukaemia
- 28 January 2019
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 129 (3) , 1047-1060
Loss of ARHGEF1 causes a human primary antibody deficiency
ARHGEF1 is a RhoA-specific guanine nucleotide exchange factor expressed in hematopoietic cells. We used whole-exome sequencing to identify compound heterozygous mutations in ARHGEF1, resulting in the loss of ARHGEF1 protein expression in two primary-antibody-deficient siblings presenting with recurrent severe respiratory tract infections and bronchiectasis. Both ARHGEF1-deficient patients showed an abnormal B cell immunophenotype, with a deficiency in marginal-zone and memory B cells and an increased frequency of transitional B cells. Furthermore, the patients’ blood contained immature myeloid cells. Analysis of a mediastinal lymph node from one patient highlighted the small size of the germinal centres and an abnormally high plasma cell content. On the molecular level, T and B lymphocytes from both patients displayed low RhoA activity and low steady-state actin polymerization (even after stimulation of lysophospholipid receptors). As a consequence of disturbed regulation of the RhoA downstream target ROCK, the patients’ lymphocytes failed to efficiently restrain AKT phosphorylation. Enforced ARHGEF1 expression or drug-induced activation of RhoA in patients’ cells corrected the impaired actin polymerization and AKT regulation. Our results indicate that ARHGEF1 activity in human lymphocytes is involved in controlling actin cytoskeleton dynamics, restraining PI3K/AKT signalling, and confining B lymphocytes and myelocytes within their dedicated functional environment.
- 28 January 2019
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 129 (3) , 1047-1060
Loss of ARHGEF1 causes a human primary antibody deficiency
ARHGEF1 is a RhoA-specific guanine nucleotide exchange factor expressed in hematopoietic cells. We used whole-exome sequencing to identify compound heterozygous mutations in ARHGEF1, resulting in the loss of ARHGEF1 protein expression in two primary-antibody-deficient siblings presenting with recurrent severe respiratory tract infections and bronchiectasis. Both ARHGEF1-deficient patients showed an abnormal B cell immunophenotype, with a deficiency in marginal-zone and memory B cells and an increased frequency of transitional B cells. Furthermore, the patients’ blood contained immature myeloid cells. Analysis of a mediastinal lymph node from one patient highlighted the small size of the germinal centres and an abnormally high plasma cell content. On the molecular level, T and B lymphocytes from both patients displayed low RhoA activity and low steady-state actin polymerization (even after stimulation of lysophospholipid receptors). As a consequence of disturbed regulation of the RhoA downstream target ROCK, the patients’ lymphocytes failed to efficiently restrain AKT phosphorylation. Enforced ARHGEF1 expression or drug-induced activation of RhoA in patients’ cells corrected the impaired actin polymerization and AKT regulation. Our results indicate that ARHGEF1 activity in human lymphocytes is involved in controlling actin cytoskeleton dynamics, restraining PI3K/AKT signalling, and confining B lymphocytes and myelocytes within their dedicated functional environment.
- 20 April 2017
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (7) , e278-e281
Mutations in the adaptor-binding domain and associated linker region of p110δ cause Activated PI3K-δ Syndrome 1 (APDS1)
Class I phosphoinositide-3-kinases (PI3Ks) convert phosphoinositol-4,5-bisphosphate to phosphoinositol-3,4,5-trisphosphate, a lipid second messenger produced mainly at plasma membranes where it recruits and activates pleckstrin homology domain-containing proteins, including the well known protein
- 20 April 2017
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (7) , e278-e281
Mutations in the adaptor-binding domain and associated linker region of p110δ cause Activated PI3K-δ Syndrome 1 (APDS1)
Class I phosphoinositide-3-kinases (PI3Ks) convert phosphoinositol-4,5-bisphosphate to phosphoinositol-3,4,5-trisphosphate, a lipid second messenger produced mainly at plasma membranes where it recruits and activates pleckstrin homology domain-containing proteins, including the well known protein
- 18 April 2017
- Published by Wiley in The Journal of Pathology
- Vol. 242 (3) , 347-357
MYB–GATA1 fusion promotes basophilic leukaemia: involvement of interleukin‐33 and nerve growth factor receptors
Acute basophilic leukaemia (ABL) is a rare subtype of acute myeloblastic leukaemia. We previously described a recurrent t(X;6)(p11;q23) translocation generating an MYB–GATA1 fusion gene in male infants with ABL. To better understand its role, the chimeric MYB–GATA1 transcription factor was expressed in CD34‐positive haematopoietic progenitors, which were transplanted into immunodeficient mice. Cells expressing MYB–GATA1 showed increased expression of markers of immaturity (CD34), of granulocytic lineage (CD33 and CD117), and of basophilic differentiation (CD203c and FcϵRI). UT‐7 cells also showed basophilic differentiation after MYB–GATA1 transfection. A transcriptomic study identified nine genes deregulated by both MYB–GATA1 and basophilic differentiation. Induction of three of these genes (CCL23, IL1RL1, and NTRK1) was confirmed in MYB–GATA1‐expressing CD34‐positive cells by reverse transcription quantitative polymerase chain reaction. Interleukin (IL)‐33 and nerve growth factor (NGF), the ligands of IL‐1 receptor‐like 1 (IL1RL1) and neurotrophic receptor tyrosine kinase 1 (NTRK1), respectively, enhanced the basophilic differentiation of MYB–GATA1‐expressing UT‐7 cells, thus demonstrating the importance of this pathway in the basophilic differentiation of leukaemic cells and CD34‐positive primary cells. Finally, gene reporter assays confirmed that MYB and MYB–GATA1 directly activated NTRK1 and IL1RL1 transcription, leading to basophilic skewing of the blasts. MYB–GATA1 is more efficient than MYB, because of better stability. Our results highlight the role of IL‐33 and NGF receptors in the basophilic differentiation of normal and leukaemic cells. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 18 April 2017
- Published by Wiley in The Journal of Pathology
- Vol. 242 (3) , 347-357
MYB–GATA1 fusion promotes basophilic leukaemia: involvement of interleukin‐33 and nerve growth factor receptors
Acute basophilic leukaemia (ABL) is a rare subtype of acute myeloblastic leukaemia. We previously described a recurrent t(X;6)(p11;q23) translocation generating an MYB–GATA1 fusion gene in male infants with ABL. To better understand its role, the chimeric MYB–GATA1 transcription factor was expressed in CD34‐positive haematopoietic progenitors, which were transplanted into immunodeficient mice. Cells expressing MYB–GATA1 showed increased expression of markers of immaturity (CD34), of granulocytic lineage (CD33 and CD117), and of basophilic differentiation (CD203c and FcϵRI). UT‐7 cells also showed basophilic differentiation after MYB–GATA1 transfection. A transcriptomic study identified nine genes deregulated by both MYB–GATA1 and basophilic differentiation. Induction of three of these genes (CCL23, IL1RL1, and NTRK1) was confirmed in MYB–GATA1‐expressing CD34‐positive cells by reverse transcription quantitative polymerase chain reaction. Interleukin (IL)‐33 and nerve growth factor (NGF), the ligands of IL‐1 receptor‐like 1 (IL1RL1) and neurotrophic receptor tyrosine kinase 1 (NTRK1), respectively, enhanced the basophilic differentiation of MYB–GATA1‐expressing UT‐7 cells, thus demonstrating the importance of this pathway in the basophilic differentiation of leukaemic cells and CD34‐positive primary cells. Finally, gene reporter assays confirmed that MYB and MYB–GATA1 directly activated NTRK1 and IL1RL1 transcription, leading to basophilic skewing of the blasts. MYB–GATA1 is more efficient than MYB, because of better stability. Our results highlight the role of IL‐33 and NGF receptors in the basophilic differentiation of normal and leukaemic cells. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- Open Access
- 1 July 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 138 (1) , 210-218.e9
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study
- 1 July 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 138 (1) , 210-218.e9
Open AccessClinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study
- Open Access
- 17 July 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (21) , 18242-18243
Hyper-activated PI3K-δ in immunodeficiency
- 17 July 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (21) , 18242-18243
Open AccessHyper-activated PI3K-δ in immunodeficiency
- Open Access
- 1 April 2015
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 125 (4) , 1764-1765
A human immunodeficiency caused by mutations in the PIK3R1 gene
- 1 April 2015
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 125 (4) , 1764-1765
Open AccessA human immunodeficiency caused by mutations in the PIK3R1 gene